EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder

Sean T Lynch, Kathryn Brooke Renard, Angelo I Chaia, Lisa J Cohen, Carisa M Kymissis

Schizophrenia Research · 2026-07 · 293 · 1-7

DOI: 10.1016/j.schres.2026.03.015 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Schizophrenia Research, 2026-07. Verfasst von Sean T Lynch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Mount Sinai Behavioral Health Center, Mount Sinai Beth Israel, Department of Psychiatry, New York, NY, USA; …. Hauptthemen laut MEDLINE: Aripiprazole, Schizophrenia, Patient Readmission, Psychotic Disorders. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Schizophrenia and schizoaffective disorder are primarily treated with antipsychotic medications, including long-acting injectables (LAIs) which help reduce relapse/readmission. New LAIs have longer duration of action, including aripiprazole which now is available in bimonthly and monthly formulations. This study aimed to examine if bimonthly aripiprazole LAI (ARI-2) led to reduced readmissions and longer time to readmission compared to monthly aripiprazole LAI (ARI-1). METHODS: This retrospective cohort study examined all patients psychiatrically hospitalized in a metropolitan health system who had the diagnosis of schizophrenia or schizoaffective disorder, and who received aripiprazole LAI between January 1, 2020 and October 13, 2022 (N = 160). Baseline sociodemographic and clinical data were collected, as well as information on readmission. Differences between ARI-1 and ARI-2 groups were examined across a 1-year period. RESULTS: ARI-1 and ARI-2 groups were largely similar in terms of baseline characteristics, with ARI-2 having more undomiciled patients and ARI-1 a greater number of prior hospitalizations. Readmission rates between the groups were similar. ARI-2 had significantly longer time to rehospitalization compared to ARI-1, by over 60 days on average. When controlling for confounding variables, such as prior hospitalizations, being undomiciled, and length of stay, only receiving ARI-2 was found to independently predict longer time to rehospitalization among those rehospitalized within 1 year. CONCLUSION: This real-world study found that receiving bimonthly aripiprazole LAI may be associated with improved outcomes over the course of one year compared to monthly, specifically in delaying time to rehospitalization. Our results are consistent with prior literature. Further research is needed to directly compare ARI-1 and ARI-2 over longer periods of time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleSchizophreniaPatient ReadmissionPsychotic DisordersAntipsychotic AgentsOutcome Assessment, Health CareHumansFemaleMaleRetrospective StudiesDelayed-Action PreparationsAdultMiddle AgedTime Factors

Stichwörter der Autor:innen

AntipsychoticsHospital psychiatryLong-acting injectablesPsychosisSchizoaffective disorderSchizophrenia

Substanzen

AripiprazoleAntipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, Mount Sinai Behavioral Health Center, Mount Sinai Beth Israel, Department of Psychiatry, New York, NY, USA; Columbia University Vagelos College of Physicians & Surgeons, New York…
  • Icahn School of Medicine at Mount Sinai, Mount Sinai Behavioral Health Center, Mount Sinai Beth Israel, Department of Psychiatry, New York, NY, USA.

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Lynch, S. T., Renard, K. B., Chaia, A. I., Cohen, L. J., & Kymissis, C. M. (2026). Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 293, 1-7. https://doi.org/10.1016/j.schres.2026.03.015

Vancouver

Lynch ST, Renard KB, Chaia AI, Cohen LJ, Kymissis CM. Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research. 2026;293:1-7. doi:10.1016/j.schres.2026.03.015

BibTeX
@article{Lynch2026,
  author = {Lynch, Sean T and Renard, Kathryn Brooke and Chaia, Angelo I and Cohen, Lisa J and Kymissis, Carisa M},
  title = {Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder},
  journal = {Schizophrenia Research},
  year = {2026},
  volume = {293},
  pages = {1--7},
  doi = {10.1016/j.schres.2026.03.015}
}
Kostenlos starten →